Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

on to the webcast at least fifteen minutes prior to the scheduled start time.  A replay of this investor event will be available on the Nektar website approximately three hours after the presentation and will be archived for four weeks.

Figure A: Efficacy Table: Objective Tumor Response Rate by RECIST (Investigator Assessment)Response by RECIST v 1.0

NKTR-102

145 mg/m²

q14d

ITT/Evaluable

NKTR-102

145 mg/m²

q21d ITT/EvaluableTOTAL

ITT/EvaluableN

35/31*

35

70/66ORR (confirmed + unconfirmed

11 (31%)/11 (35%)

11 (31%)

22 (31%)/22 (33%)ORR (confirmed)

10 (29%)/10 (32%)

9 (26%)

19 (27%)/19 (29%)CR (confirmed)

2 (6%)/2 (7%)

0

2 (3%)/2 (3%)PR (confirmed)

8 (23%)/8 (26%)

9 (26%)

17 (24%)/17 (26%)SD

17 (48%)/13 (42%)

17 (48%)

34 (49%)/30 (45%)PD

8 (23%)/8 (26%)

9 (26%)

17 (24%)/17 (26%)Clinical benefit

(CR+PR+SD greater than or equal to 6 months)

12 (34%)/12 (39%)

15 (43%)

27 (38%)/27 (41%)*4 patients in the Q14 day arm with no post-baseline scans, but no evidence of progression were excluded from analysis in the evaluable population.Figure B: Efficacy Table: Response rate by prior therapyPrior Therapy Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m²

q14d

N=31

NKTR-102

145 mg/m²

q21d

N=35TOTALPrior A/T only

ORR (confirmed)

7/22 (32%) 5/21 (24%)12/43 (28%)Prior A/T in MBC

ORR (confirmed)

2/6 (33%)

2/8 (25%)

4/14 (29%)Prior A/T/C

ORR (confirmed)

2/6 (33%)

3/9 (33%)5/15 (33%)Figure C: Efficacy Table: Response rate by tumor characteristicsDisease Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m²

q14d

N=31

<
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Radiologist Delivers Chemo Drug Directly to Eye via,Ophthalmic ... interventional,radiology treatment successfully treats advanced retinoblastoma -- a,deadly, ... children -- and often,spares them from having their ... a study released today at the Society of,Interventional ...
... Dependent on Outcomes of New Analyses or Confirmatory ... for Tuesday March 18, 2008, BERKELEY HEIGHTS, ... ) announced that the Food and Drug,Administration,s (FDA) ... that available data are not adequate to support ...
Cached Medicine Technology:New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 2FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 3FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 4FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 5FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data 6
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
(Date:4/22/2014)... LAKE CITY)A computational tool developed at the University of ... unknown gene mutations in three separate cases, U of ... study in The American Journal of Human Genetics ... tool), identifies undiagnosed illnesses and unknown gene mutations by ... that code for genes are made, in individual patients ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3
... The Company,s Commitment to Healthy and Successful Vascular ... Lifeline Vascular Access(SM), the nation,s leading provider ... its network of managed vascular access centers has ... with the Lifeline Vascular Access managed center Nephrology ...
... their full range of 7Fr IAB catheters and immediate release in the ... ... Insightra Medical Inc. , a privately held medical device company based in ... sizes including: 40cc, 35cc, 30cc, 25cc and 20cc, all in a true ...
... bleeding inside the heart after people have suffered a heart ... published today in the journal Radiology . , The ... damaged a person,s heart is after a heart attack. The ... London, hope that this kind of imaging will be used ...
... Boston, MA A collection of hospitals in eight cities ... a simple surgical checklist during major operations can lower the ... The year-long study was led by researchers from the Harvard ... Health Organization, and the results are published Online First on ...
... during breast-feeding, but resistant disease can develop in first ... -- The antiretroviral drug nevirapine may help prevent babies ... but it also greatly increases the odds of developing ... year of life, a new study finds. , Still, ...
... company, Oral BioTech, is embracing this new research on xylitol with ... Part of the motivation for these products has been the relative ... products. , ... Albany, OR (PRWEB) January 18, 2009 ...
Cached Medicine News:Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 2Health News:Insightra Medical, Inc. Gains FDA clearance for the Most Complete Range of 7Fr Intra Aortic Balloon (IAB) Catheters 3Health News:Bleeding hearts revealed with new scan 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 2Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 3Health News:Hospitals demonstrate surgical safety checklist drops deaths and complications by more than a third 4Health News:HIV Drug a Double-Edged Sword for Infants 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 2Health News:Keeping Kids Cavity-Free Before They're Ever Born: CariFree Believes Xylitol Could be This Generation's Answer 3
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Serrated, 10 mm tips angled 30 degrees. Serrated cross action handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide smooth handle with polished finish....
Medicine Products: